TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

Hope S. Rugo; Aditya Bardia; Sara M. Tolaney; Carlos Arteaga; Javier Cortes; Joohyuk Sohn; Frederik Marmé; Quan Hong; Rosemary J. Delaney; Amir Hafeez; Fabrice André; Peter Schmid

doi:10.2217/fon-2020-0163

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

Hope S. Rugo, Aditya Bardia, Sara M. Tolaney, Carlos Arteaga, Javier Cortes, Joohyuk Sohn, Frederik Marmé, Quan Hong, Rosemary J. Delaney, Amir Hafeez, Fabrice André, Peter Schmid

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

83 Citations (Scopus)

Résumé

Patients with HR+/HER2-metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2-MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2-MBC. Trial registration number: NCT03901339.

langue originale	Anglais
Pages (de - à)	705-712
Nombre de pages	8
journal	Future Oncology
Volume	16
Numéro de publication	12
Les DOIs	https://doi.org/10.2217/fon-2020-0163
état	Publié - 1 avr. 2020

Accès au document

10.2217/fon-2020-0163

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{12178d8091004b5bbd43e46787a7f2f4,

title = "TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer",

abstract = "Patients with HR+/HER2-metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2-MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2-MBC. Trial registration number: NCT03901339.",

keywords = "HER2-negative, HR-positive, MBC, SN-38, Trop-2, antibody-drug conjugate, metastatic breast cancer, sacituzumab govitecan",

author = "Rugo, {Hope S.} and Aditya Bardia and Tolaney, {Sara M.} and Carlos Arteaga and Javier Cortes and Joohyuk Sohn and Frederik Marm{\'e} and Quan Hong and Delaney, {Rosemary J.} and Amir Hafeez and Fabrice Andr{\'e} and Peter Schmid",

note = "Publisher Copyright: {\textcopyright} 2020 Hope S. Rugo, MD.",

year = "2020",

month = apr,

day = "1",

doi = "10.2217/fon-2020-0163",

language = "English",

volume = "16",

pages = "705--712",

journal = "Future Oncology",

issn = "1479-6694",

number = "12",

}

TY - JOUR

T1 - TROPiCS-02

T2 - A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

AU - Rugo, Hope S.

AU - Bardia, Aditya

AU - Tolaney, Sara M.

AU - Arteaga, Carlos

AU - Cortes, Javier

AU - Sohn, Joohyuk

AU - Marmé, Frederik

AU - Hong, Quan

AU - Delaney, Rosemary J.

AU - Hafeez, Amir

AU - André, Fabrice

AU - Schmid, Peter

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Patients with HR+/HER2-metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2-MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2-MBC. Trial registration number: NCT03901339.

AB - Patients with HR+/HER2-metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2-MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2-MBC. Trial registration number: NCT03901339.

KW - HER2-negative

KW - HR-positive

KW - MBC

KW - SN-38

KW - Trop-2

KW - antibody-drug conjugate

KW - metastatic breast cancer

KW - sacituzumab govitecan

UR - http://www.scopus.com/inward/record.url?scp=85083883116&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-0163

DO - 10.2217/fon-2020-0163

M3 - Article

C2 - 32223649

AN - SCOPUS:85083883116

SN - 1479-6694

VL - 16

SP - 705

EP - 712

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -